

Table 9A.8.1: Bone Sarcoma 2- and 5-Year Survival Estimates by Type of Cancer, United States, 1998-2011

Type	Total N	2 Year Survival (95% CI)	5 Year Survival (95% CI)
Chondrosarcoma, NOS	3855	86.4% (85.3%, 87.5%)	77.7% (76.3%, 79.0%)
Osteosarcoma, NOS	2037	65.0% (62.8%, 67.1%)	49.0% (46.7%, 51.2%)
Ewing sarcoma	1146	62.0% (59.0%, 64.8%)	41.5% (38.4%, 44.5%)
Chondroblastic osteosarcoma	456	69.8% (65.3%, 73.9%)	53.0% (48.1%, 57.7%)
Myxoid chondrosarcoma	381	81.0% (76.5%, 84.7%)	66.7% (61.5%, 71.5%)
Sarcoma, Spindle Cell, Undifferentiated and NOS	347	43.3% (37.9%, 48.6%)	29.5% (24.5%, 34.6%)
Fibrous histiocytoma, malignant	317	60.2% (54.5%, 65.5%)	43.8% (38.0%, 49.4%)
Fibroblastic osteosarcoma	238	80.0% (74.3%, 84.6%)	61.5% (54.8%, 67.5%)
Dedifferentiated chondrosarcoma	223	31.9% (25.7%, 38.2%)	21.6% (16.3%, 27.5%)
Parosteal osteosarcoma	205	93.5% (88.8%, 96.2%)	88.1% (82.3%, 92.1%)
Hemangiosarcoma	153	33.8% (26.3%, 41.6%)	25.4% (18.5%, 32.8%)
Fibrosarcoma, NOS	96	66.1% (55.3%, 74.8%)	55.2% (44.2%, 64.9%)
Peripheral/Primitive neuroectodermal and Askin tumor	91	62.8% (51.7%, 72.1%)	42.8% (32.0%, 53.2%)
Mesenchymal chondrosarcoma	87	72.9% (62.1%, 81.1%)	56.8% (45.5%, 66.7%)
Telangiectatic osteosarcoma	86	65.0% (53.6%, 74.2%)	52.2% (40.8%, 62.4%)
Leiomyosarcoma, NOS	85	73.8% (62.7%, 82.1%)	46.2% (34.4%, 57.2%)
Adamantinoma of long bones	58	98.2% (88%, 99.7%)	91.8% (79.5%, 96.9%)
Juxtacortical chondrosarcoma	56	98.2% (87.8%, 99.7%)	96.3% (85.8%, 99.1%)
Periosteal osteosarcoma	40	89.7% (74.9%, 96%)	73.4% (56.1%, 84.8%)
Clear cell chondrosarcoma	40	94.7% (80.4%, 98.7%)	91.8% (76.7%, 97.3%)
Total	9,997		

Source: American College of Surgeons National Cancer Data Base (NCDB).

NOTE: NCDB Adult Bone Sarcoma Data Summary

Demographic data was available on adult (18 years old and older) cases diagnosed from 1998 – 2011. A total of 21,922 cases were available, of which we selected the 18,580 cases with the greatest frequency of diagnosis. Two- and 5-year mortality was only available for 11,684 cases from 1998 – 2006. We selected the following 9,997 cases to report in tabular form. The sample size by cancer type is provided in the tables. The difference in sample size is related to excluding cases without follow up data. Per NCDB, mortality data is not available for the last five years of collection (2007-2011). Also, per NCDB, cases were excluded if they had multiple cancer types.

The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data used in this study and this report are derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator and authors of this work.